search
Back to results

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled Montelukast (MK-0476) in Participants With Mild or Moderate Asthma (MK-0476-380 AM3)(COMPLETED)

Primary Purpose

Asthma

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Montelukast
Placebo
Sponsored by
Organon and Co
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female between the ages of 18 and 65
  • Must have mild or moderate asthma (Part III only)
  • Nonsmoker for at least 6 months

Exclusion Criteria:

  • History of stroke, chronic seizures or major neurological disorder
  • You are nursing
  • Drink more than 3 glasses of alcohol a day
  • Have allergy to or not able to tolerate lactose
  • Have a history of drug abuse in the last 5 years
  • Drink more than 6 beverages containing caffeine a day
  • Have had surgery, donated blood or participated in another investigational study in the last 4 weeks

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm 5

    Arm 6

    Arm Type

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Placebo Comparator

    Arm Label

    Montelukast 0.1 mg

    Montelukast 0.3 mg

    Montelukast 1 mg

    Montelukast 3 mg

    Montelukast 10 mg

    Placebo

    Arm Description

    Participants receive Montelukast inhalation powder, 0.1 mg. Part I: Administered as a single dose followed by at least a 3-day washout period.

    Participants receive Montelukast inhalation powder, 0.3 mg. Part I: Administered as a single dose followed by at least a 3-day washout period.

    Participants receive Montelukast inhalation powder, 1 mg. Part I: Administered as a single dose followed by at least a 3-day washout period. Part II: Administered once daily (QD) for 5 days followed by at least a 3-day washout period.

    Participants receive Montelukast inhalation powder, 3 mg. Part I: Administered as a single dose followed by at least a 3-day washout period. Part II: Administered QD for 5 days followed by at least a 3-day washout period. Part III: Administered QD for 10 days followed by at least a 7-day washout period.

    Participants receive Montelukast inhalation powder, 10 mg. Part I: Administered as a single dose followed by at least a 3-day washout period. Part II: Administered QD for 5 days followed by at least a 3-day washout period. Part III: Administered QD for 10 days followed by at least a 7-day washout period.

    Participants receive Placebo to Montelukast inhalation powder. Part I: Administered as a single dose followed by at least a 3-day washout period. Part II: Administered QD for 5 days followed by at least a 3-day washout period. Part III: Administered QD for 10 days followed by at least a 7-day washout period.

    Outcomes

    Primary Outcome Measures

    Number of Participants Who Experienced At Least One Adverse Event
    Number of Participants Who Discontinued Study Drug Due to an Adverse Event
    Area Under the Curve From 0 to 24 Hours (AUC 0-24hr) of Montelukast - Single Dose
    Blood samples for assessment of AUC 0-24hr were drawn predose and then at specified timepoints (up to 24 hours postdose) on Day 1 in Part I.
    AUC 0-24hr of Montelukast - Multiple Doses
    Blood samples for assessment of AUC 0-24hr were drawn predose and then at specified timepoints (up to 24 hours postdose) on Days 1 and 5 in Part II and on Days 1 and 10 in Part III.
    Maximum Plasma Concentration (Cmax) of Montelukast - Single Dose
    Blood samples for assessment of Cmax were drawn predose and then at specified timepoints (up to 24 hours postdose) on Day 1 in Part I.
    Cmax of Montelukast - Multiple Doses
    Blood samples for assessment of Cmax were drawn predose and then at specified timepoints (up to 24 hours postdose) on Days 1 and 5 in Part II and on Days 1 and 10 in Part III.
    Time to Cmax (Tmax) of Montelukast - Single Dose
    Blood samples for assessment of Tmax were drawn predose and then at specified timepoints (up to 24 hours postdose) on Day 1 in Part I.
    Tmax of Montelukast - Multiple Doses
    Blood samples for assessment of Tmax were drawn predose and then at specified timepoints (up to 24 hours postdose) on Days 1 and 5 in Part II and on Days 1 and 10 in Part III.
    Apparent Terminal Half Life (t1/2) of Montelukast - Single Dose
    Blood samples for assessment of t1/2 were drawn predose and then at specified timepoints (up to 24 hours postdose) on Day 1 in Part I.
    t1/2 of Montelukast - Multiple Doses
    Blood samples for assessment of t1/2 were drawn predose and then at specified timepoints (up to 24 hours postdose) on Days 1 and 5 in Part II and on Days 1 and 10 in Part III.
    AUC 0-24hr Accumulation Ratio of Montelukast - Multiple Doses
    The AUC 0-24hr Accumulation Ratio of Montelukast was calculated as the geometric mean ratio of AUC 0-24hr on the last day and the first day of a multiple dose regimen: Day 5/Day 1 in Part II and Day 10/Day 1 in Part III.
    Cmax Accumulation Ratio of Montelukast - Multiple Doses
    The Cmax Accumulation Ratio of Montelukast was calculated as the geometric mean ratio of Cmax on the last day and the first day of a multiple dose regimen: Day 5/Day 1 in Part II and Day 10/Day 1 in Part III.

    Secondary Outcome Measures

    Full Information

    First Posted
    March 3, 2008
    Last Updated
    February 7, 2022
    Sponsor
    Organon and Co
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00636207
    Brief Title
    A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled Montelukast (MK-0476) in Participants With Mild or Moderate Asthma (MK-0476-380 AM3)(COMPLETED)
    Official Title
    A Sequential, 3-Part, Double-Blind, Randomized, Placebo-Controlled, Single-Rising-Dose and Rising-Multiple-Dose Study in Healthy Subjects and Mild or Moderate Asthmatic Patients to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled MK-0476
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2022
    Overall Recruitment Status
    Completed
    Study Start Date
    August 2007 (undefined)
    Primary Completion Date
    September 2008 (Actual)
    Study Completion Date
    October 2008 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Organon and Co

    4. Oversight

    5. Study Description

    Brief Summary
    A study to evaluate the safety, tolerability and pharmacokinetics of inhaled Montelukast (MK-0476) in participants with mild or moderate asthma.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Asthma

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    46 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Montelukast 0.1 mg
    Arm Type
    Experimental
    Arm Description
    Participants receive Montelukast inhalation powder, 0.1 mg. Part I: Administered as a single dose followed by at least a 3-day washout period.
    Arm Title
    Montelukast 0.3 mg
    Arm Type
    Experimental
    Arm Description
    Participants receive Montelukast inhalation powder, 0.3 mg. Part I: Administered as a single dose followed by at least a 3-day washout period.
    Arm Title
    Montelukast 1 mg
    Arm Type
    Experimental
    Arm Description
    Participants receive Montelukast inhalation powder, 1 mg. Part I: Administered as a single dose followed by at least a 3-day washout period. Part II: Administered once daily (QD) for 5 days followed by at least a 3-day washout period.
    Arm Title
    Montelukast 3 mg
    Arm Type
    Experimental
    Arm Description
    Participants receive Montelukast inhalation powder, 3 mg. Part I: Administered as a single dose followed by at least a 3-day washout period. Part II: Administered QD for 5 days followed by at least a 3-day washout period. Part III: Administered QD for 10 days followed by at least a 7-day washout period.
    Arm Title
    Montelukast 10 mg
    Arm Type
    Experimental
    Arm Description
    Participants receive Montelukast inhalation powder, 10 mg. Part I: Administered as a single dose followed by at least a 3-day washout period. Part II: Administered QD for 5 days followed by at least a 3-day washout period. Part III: Administered QD for 10 days followed by at least a 7-day washout period.
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    Participants receive Placebo to Montelukast inhalation powder. Part I: Administered as a single dose followed by at least a 3-day washout period. Part II: Administered QD for 5 days followed by at least a 3-day washout period. Part III: Administered QD for 10 days followed by at least a 7-day washout period.
    Intervention Type
    Drug
    Intervention Name(s)
    Montelukast
    Other Intervention Name(s)
    Montelukast Sodium, MK-0476
    Intervention Description
    Montelukast dry powder inhaler, 0.1 mg, 0.3 mg, 1 mg, 3 mg or 10 mg
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Intervention Description
    Placebo dry powder inhaler
    Primary Outcome Measure Information:
    Title
    Number of Participants Who Experienced At Least One Adverse Event
    Time Frame
    Up to 14 days after last dose of study drug
    Title
    Number of Participants Who Discontinued Study Drug Due to an Adverse Event
    Time Frame
    Up to 7 days after last dose of study drug
    Title
    Area Under the Curve From 0 to 24 Hours (AUC 0-24hr) of Montelukast - Single Dose
    Description
    Blood samples for assessment of AUC 0-24hr were drawn predose and then at specified timepoints (up to 24 hours postdose) on Day 1 in Part I.
    Time Frame
    Up to 24 hours postdose
    Title
    AUC 0-24hr of Montelukast - Multiple Doses
    Description
    Blood samples for assessment of AUC 0-24hr were drawn predose and then at specified timepoints (up to 24 hours postdose) on Days 1 and 5 in Part II and on Days 1 and 10 in Part III.
    Time Frame
    Up to 24 hours postdose
    Title
    Maximum Plasma Concentration (Cmax) of Montelukast - Single Dose
    Description
    Blood samples for assessment of Cmax were drawn predose and then at specified timepoints (up to 24 hours postdose) on Day 1 in Part I.
    Time Frame
    Up to 24 hours postdose
    Title
    Cmax of Montelukast - Multiple Doses
    Description
    Blood samples for assessment of Cmax were drawn predose and then at specified timepoints (up to 24 hours postdose) on Days 1 and 5 in Part II and on Days 1 and 10 in Part III.
    Time Frame
    Up to 24 hours postdose
    Title
    Time to Cmax (Tmax) of Montelukast - Single Dose
    Description
    Blood samples for assessment of Tmax were drawn predose and then at specified timepoints (up to 24 hours postdose) on Day 1 in Part I.
    Time Frame
    Up to 24 hours postdose
    Title
    Tmax of Montelukast - Multiple Doses
    Description
    Blood samples for assessment of Tmax were drawn predose and then at specified timepoints (up to 24 hours postdose) on Days 1 and 5 in Part II and on Days 1 and 10 in Part III.
    Time Frame
    Up to 24 hours postdose
    Title
    Apparent Terminal Half Life (t1/2) of Montelukast - Single Dose
    Description
    Blood samples for assessment of t1/2 were drawn predose and then at specified timepoints (up to 24 hours postdose) on Day 1 in Part I.
    Time Frame
    Up to 24 hours postdose
    Title
    t1/2 of Montelukast - Multiple Doses
    Description
    Blood samples for assessment of t1/2 were drawn predose and then at specified timepoints (up to 24 hours postdose) on Days 1 and 5 in Part II and on Days 1 and 10 in Part III.
    Time Frame
    Up to 24 hours postdose
    Title
    AUC 0-24hr Accumulation Ratio of Montelukast - Multiple Doses
    Description
    The AUC 0-24hr Accumulation Ratio of Montelukast was calculated as the geometric mean ratio of AUC 0-24hr on the last day and the first day of a multiple dose regimen: Day 5/Day 1 in Part II and Day 10/Day 1 in Part III.
    Time Frame
    up to 10 days after first dose of study drug
    Title
    Cmax Accumulation Ratio of Montelukast - Multiple Doses
    Description
    The Cmax Accumulation Ratio of Montelukast was calculated as the geometric mean ratio of Cmax on the last day and the first day of a multiple dose regimen: Day 5/Day 1 in Part II and Day 10/Day 1 in Part III.
    Time Frame
    up to 10 days after first dose of study drug

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Male or female between the ages of 18 and 65 Must have mild or moderate asthma (Part III only) Nonsmoker for at least 6 months Exclusion Criteria: History of stroke, chronic seizures or major neurological disorder You are nursing Drink more than 3 glasses of alcohol a day Have allergy to or not able to tolerate lactose Have a history of drug abuse in the last 5 years Drink more than 6 beverages containing caffeine a day Have had surgery, donated blood or participated in another investigational study in the last 4 weeks
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Medical Monitor
    Organizational Affiliation
    Merck Sharp & Dohme LLC
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

    Learn more about this trial

    A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled Montelukast (MK-0476) in Participants With Mild or Moderate Asthma (MK-0476-380 AM3)(COMPLETED)

    We'll reach out to this number within 24 hrs